oncology
GU Cancer

New antiandrogen extends survival in high risk early prostate cancer

Improved survival rates have been seen in a study of apalutamide in high risk men with non-metastatic castration-resistant prostate cancer. A phase 3 trial of the androgen receptor inhibitor versus placebo for men with non-metastatic prostate cancer has shown the drug can extend metastasis-free survival by over two years. The SPARTAN study, published this week ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic